Charles Halpern Letter to ICOC
By Charles Halpern
| 01. 03. 2005
Dear Members of the ICOC:
I reviewed the agenda for the January 6 meeting with concern and surprise. I find that the Bagley-Keene Open Meetings Act is still not being complied with and that the Committee is being invited to rush into the core of its work without having laid an appropriate foundation.
I write to encourage you to take charge of the mission of the Institute and to begin to function as a deliberative body, allowing due time for serious consideration of complex issues, with public involvement in the manner prescribed by California law.
I suggest that the ICOC take the following steps:
1. Clarify the scope of the program.
Though there is an unfortunate ambiguity in the intertwined provisions of Prop. 71, it is clear that the Institute for Regenerative Medicine is not limited to supporting embryonic stem cell research. It is authorized to support a broad range of medical research intended to cure or mitigate disease. How will the ICOC define the mandate? Will the construction grants that are likely to loom large in the first year's...
Related Articles
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...
By Pat Duggins, Alabama Public Radio | 06.27.2025
PAT DUGGINS-- If I were to say, ‘man, have you seen the price of eggs these days?’ You're probably thinking, Oh, he's talking about inflation and the price of groceries and how it became an issue in the presidential race...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Staff, The Associated Press | 06.10.2025
PORTLAND, Ore. — Twenty-seven states and the District of Columbia on Monday filed a lawsuit in bankruptcy court seeking to block the sale of personal genetic data by 23andMe without customer consent. The lawsuit comes as a biotechnology company seeks...